Endocrine Abstracts

Background: Bone metastasis from gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) was once considered rare, but prevalence has recently been reported as high as 12%. Although bone metastasis has been associated with poor prognosis, the most frequent cause of mortality in this population remains liver failure when liver metastases are present. Thus, it remains unclear whether patients with concurrent liver and bone metastasis who receive liver directed therapy (LDT) w...

Background: Surufatinib, an oral small molecule tyrosine kinase inhibitor, selectively inhibits vascular endothelial growth factor receptor 1, 2, and 3; fibroblast growth factor receptor 1; and colony-stimulating factor 1 receptor. Tislelizumab is a humanized immunoglobulin G4-variant anti-programmed cell death protein-1 monoclonal antibody. Combining surufatinib and tislelizumab may have synergistic effects, where inhibition of angiogenesis and stimulation of an immune respon...